We Are This Close to "Designer Babies"
By Nina Liss-Schultz,
Mother Jones
| 02. 08. 2016
[cites CGS' Marcy Darnovsky]
Untitled Document
On February 1, scientists from the United Kingdom's Francis Crick Institute got the okay to start research on human embryos using a new genome editing technology called CRISPR. Their work, which will mark only the second time CRISPR has been applied to humans, will use embryos to try to understand the very early stages of human development and pinpoint the genes causing miscarriages and fetal defects.
Not surprisingly, the Crick project has reignited a firestorm of debate over the ethics of human gene editing. "This is the first step in a well mapped-out process heading to genetically modified babies, and a future of consumer eugenics," said Dr. David King, director of Human Genetics Alert, in response to the news.
CRISPR is essentially a cellular scalpel. The small enzyme works by moving through the body's cells and cutting away at precise pieces of the genome—something that's never before been possible to do with such efficiency and ease. Since 2012, it's been used to cut out the gene mutations leading to HIV and sickle cell anemia. Last spring...
Related Articles
By Matt Novak, Gizmodo | 07.23.2025
Robert F. Kennedy Jr., the Secretary of Health and Human Services, has made a big push to get agencies like the Food and Drug Administration to use generative artificial intelligence tools. In fact, Kennedy recently told Tucker Carlson that AI...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...